BRUKINSA monotherapy is approved by HSE for the treatment of adults with MZL who have received at least one prior anti-CD20-based therapy.3
BRUKINSA achieved deep and sustained responses in patients with R/R MZL4
Marginal zone lymphoma
Primary endpoint: IRC-assessed ORR
Median follow-up: 28.0 months
Adapted from Opat, et al. 2023.4
ORR by MZL subtype
Extranodal
64%
CR 40%
(n=25)
Nodal
76%
CR 20%
(n=25)
Splenic
67%
CR 8%
(n=12)
Median time to response
2.8 Months
Secondary endpoint: Investigator-assessed PFS
Median follow-up: 27.4 months
Adapted from Opat, et al. 2023.4
Rate of atrial fibrillation or flutter
Any-grade:
3%
(n=2/68)
Grade ≥3:
1.5%
(n=1/68)
Dose reduction rate due to AEs
0%
(n=0/68)
Discontinuation rate due to AEs
7%
(n=5/68)
Median duration of treatment: 24.2 months
